Announcing a New Era in Alzheimer's (y 2)

        
        1) Wischik CM, Bentham P, Wischik DJ, Seng KM. Tau aggregation inhibitor
          (TAI) therapy with rember[TM] arrests disease progression in mild and moderate
          Alzheimer's disease over 50 weeks. Alzheimer's and Dementia 2008;4:T167. Abstract
          available at: http://www.alzheimersanddementia.com/article/S1552-5260(08)0...
          . Accessed October 2012.
        2) ClinicalTrials.gov. Safety and efficacy study evaluating TRx0237 in subjects
          with mild to moderate Alzheimer's disease. Available at:
          http://www.clinicaltrials.gov/ct2/show/N.... Accessed October 2012.
        3) ClinicalTrials.gov. Safety and efficacy study evaluating TRx0237 in subjects
          with mild Alzheimer's disease. Available at:
          http://www.clinicaltrials.gov/ct2/show/N.... Accessed October 2012.
        4) Wischik CM, Edwards PC, Lai RYK, Roth M, Harrington CR. Selective inhibition
          of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA
          1996;93:11213-11218. Full article available at:
          http://www.ncbi.nlm.nih.gov/pmc/articles.... Accessed October 2012.
        5) Wischik CM, Lai RYK, Harrington CR. Modelling prion-like processing of tau
          protein in Alzheimer's disease for pharmaceutical development. In: Brain
          MicrotubuleAssociated Proteins: Modifications in Disease, eds. Avila J, Brandt R,
          Kosik KS. (1997) pp. 185-241. Amsterdam: Harwood Academic Publishers.
        6) Wischik CM, Wischik DJ, Storey JMD, Harrington CR. Rationale for
          tau-aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. In:
          Emerging Drugs and Targets for Alzheimer's Disease. Volume 1: Beta-Amyloid, Tau
          Protein and Glucose Metabolism, ed. Martinez A. (2010) pp. 210-232. Cambridge: RSC
          Publishing.
        7) Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, et al.
          Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols,
          and porphyrins. J Biol Chem 2005;280:7614-7623. Full article available at:
          http://www.jbc.org/content/280/9/7614.lo.... Accessed October 2012.
        8) Alzheimer A. On a peculiar disease of the cerebral cortex. Allgemeine
          Zeitschrift fuer Psychiatrie und Psychisch-Geritlich Medicin 1907;64:146-148.
        9) World Health Organization News Release. Dementia cases set to triple by 2050
          but still largely ignored. Available at:
          http://www.who.int/mediacentre/news/rele....
          Accessed October 2012.
          10) Mukaetova-Ladinska EB, Garcia-Sierra F, Hurt J, Gertz HJ, Xuereb JH, Hills
          R, et al. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals
          biphasic synaptic protein response during progression of Alzheimer's disease. Am J
          Pathol 2000;157:623-636. Full article available at:
          http://www.ncbi.nlm.nih.gov/pmc/articles.... Accessed October 2012.
          11) Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes.
          Acta Neuropathol 1991;82:239-259. Abstract available at:
          http://www.ncbi.nlm.nih.gov/pubmed/17595.... Accessed October 2012.
          12) Soto C. Transmissible proteins: expanding the prion heresy. Cell 2012;
          149:968-977. Full article available at:
          http://www.sciencedirect.com/science/art.... Accessed
          October 2012.

CONTACT: For press enquiries please contact: U.S. media contacts:Liz Moench +1-610-659-5093; Courtney Hollinger +1-484-674 6800; Outside theU.S. media contacts: Richard Anderson +44(0)7973-950376, Email:press@taurx.com